Acceptability of the etonogestrel-containing contraceptive implant (Implanon®);Acceptabilité de l'implant contraceptif à l'étonogestrel (Implanon®)

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 5, 2004, Pages 407-415

  Sergent, F ^a   Clamageran, C ^a   Bastard, A M ^a   Verspyck, E ^a   Marpeau, L ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Bleeding irregularity; Contraceptive implant; Tolerability; Weight gain

Indexed keywords

CONTRACEPTIVE AGENT; ETONOGESTREL; LEVONORGESTREL;

ABDOMINAL PAIN; ACNE; ALOPECIA; AMENORRHEA; ARTICLE; AXILLARY LYMPH NODE; BLEEDING; CELLULITIS; CHILDBIRTH; CONTRACEPTION; DEVICE REMOVAL; DISEASE DURATION; FAMILY PLANNING; FEMALE; HEADACHE; HUMAN; IMPLANT; LIBIDO DISORDER; LONG TERM CARE; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALAISE; MASTALGIA; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MOOD DISORDER; NERVOUSNESS; PARESTHESIA; PATIENT COUNSELING; PATIENT SATISFACTION; PELVIS PAIN SYNDROME; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

EID: 4544385008     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0368-2315(04)96548-9     Document Type: Article

References (20)

1. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception 1998; 55: 91S-97S.
2. Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med 2001; 19: 339-54.
3. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69: 714-21.
4. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998; 55: 998-1078.
5. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 55: 1098-1158.
6. Bricaire C, Plu-Bureau G. Contraception hormonale. Encycl Med Chir (Éditions Scientifiques et Médicales Elsevier SAS, Paris), Gynécologie, 738-A-10, 2000.
7. Ba MG, Moreau JC, Diadhiou F. Tolérance et acceptabilité des implants contraceptifs Norplant®. J Gynecol Obstet Biol Reprod 2002; 31: 765-71.
8. Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999; 24: 3-16.
9. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999; 14: 976-81.
10. Reuter S, Smith A. Implanon: user views in the first year across three family planning services in the Trent Region, UK. Eur J Contracept Reprod Health Care 2003; 8: 27-36.
11. Meirik O, Fraser IS, d'Arcangues C; WHO Consultation on Implantable Contraceptives for Women, Implantable contraceptives for women. Hum Reprod Update 2003; 9: 49-59.
12. Mascarenhas L. Insertion and removal of Implanon. Contraception 1998; 58: 79S-83S.
13. Brache V, Faundes A, Alvarez F. Risk-benefit effects of implantable contraceptives in women. Expert Opin Drug Saf 2003; 2: 321-32.
14. Smith A, Reuter S. An assessment of the use of Implanon in three community services. J Fam Plann Reprod Health Care 2002; 28: 193-6.
15. Mascarenhas L, van Beek A, Bennink HC, Newton J. Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception 1998; 58: 215-9.
16. Biswas A, Viegas OA, Coeling Bennink HJ, Korver T, Ratnam SS. Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 2001; 63: 137-41.
17. Biswas A, Viegas OA, Roy AC. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids: a randomized comparative study. Contraception 2003; 68: 189-93.
18. Egberg N, van Beek A, Gunnervik C, Hulkko S, Hirvonen E, Larsson-Cohn U et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception 1998; 58: 93-8.
19. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65: 29-37.
20. Gaspard U, Buicu C, van den Brule F. Nouvelles formes de contraception stéroïdienne. J Gynecol Obstet Biol Reprod 2000; 29: 288-91.